Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Lessons From Lockdown: HCC and Liver Transplant Care in the COVID-19 Era—Audio Recap

In this engaging dialogue, 2 expert hepatologists discuss strategies for maintaining and even improving care of patients with HCC or liver transplantation despite the challenges posed by the COVID-19 pandemic.
Graham R. Foster, FRCP, PhD
Paul Y. Kwo, MD
Released: March 23, 2022

In this episode, Graham R. Foster, FRCP, PhD, and Paul Y. Kwo, MD, share lessons learned in the management of HCC and liver transplantation the COVID-19 era, including:

  • Global impact of HCC and strategies for maintaining HCC care in the COVID-19 era
  • Characteristics of liver transplant recipients in the COVID-19 era
  • Impact of COVID-19 pandemic period on liver transplant outcomes
  • Impact of liver transplant status on COVID-19 outcomes

Information on this Educational Activity


Graham R. Foster, FRCP, PhD

Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom

Graham R. Foster, FRCP, PhD, has disclosed that he has received consulting fees from Biogen, GlaxoSmithKline, and UniQure and fees for non-CME/CE services from AbbVie, Gilead Sciences, and MSD.
Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Aligos, Antios, Drug Farm, Enanta, Gilead Sciences, and Janssen and funds for research support from Assembly, Bristol-Myers Squibb, Eiger, Gilead Sciences, and Janssen.

Program Medium

This program has been made available online.


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by:
Gilead Sciences, Inc.

Related Content

Dr Stefan Zeuzem discusses his take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Stefan Zeuzem, MD Released: December 5, 2022

Dr Nancy Reau discusses her take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 2, 2022

Prof George Lau: proactive monitoring and treatment are necessary for all patients with CHB, regardless of age, from Clinical Care Options (CCO)

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: December 1, 2022

Expert summaries of AASLD, EASL, APASL guidance on monitoring and treating chronic hepatitis B and delta infections, with Maria Buti, Paul Kwo, Grace Wong

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings